2-(3-Cyano-phenyl)-5-tetrazol-1-ylmethyl-2H-pyrazole-3-carboxylic acid (4-benzoimidazol-1-yl-phenyl)-amide | 848393-51-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-(3-Cyano-phenyl)-5-tetrazol-1-ylmethyl-2H-pyrazole-3-carboxylic acid (4-benzoimidazol-1-yl-phenyl)-amide
• CAS: 848393-51-1
• 化学式: C₂₆H₁₈N₁₀O
• 分子量: 486.495
• InChiKey: CGNFGYMRQCPQLH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.37
• 重原子数：
  37.0
• 可旋转键数：
  6.0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  132.13
• 氢给体数：
  1.0
• 氢受体数：
  10.0

反应信息

• 作为反应物：
  描述：

  2-(3-Cyano-phenyl)-5-tetrazol-1-ylmethyl-2H-pyrazole-3-carboxylic acid (4-benzoimidazol-1-yl-phenyl)-amide 在 盐酸 、 甲醇 、 碳酸氢铵 作用下， 以 乙醇 为溶剂， 生成 2-(3-Carbamimidoyl-phenyl)-5-tetrazol-1-ylmethyl-2H-pyrazole-3-carboxylic acid (4-benzoimidazol-1-yl-phenyl)-amide
  参考文献：
  名称：

  SAR and factor IXa crystal structure of a dual inhibitor of factors IXa and Xa

  摘要：

  Modifications to the P4 moiety and pyrazole C3 substituent of factor Xa inhibitor SN-429 provided several new compounds, which are 5-10nM inhibitors of factor IXa. An X-ray crystal structure of one example complexed to factor IXa shows that these compounds adopt a similar binding mode to that previously observed with pyrazole inhibitors in the factor Xa active site both with regard to how the inhibitor binds and the position of Tyr99.

  DOI：

  10.1016/j.bmcl.2004.08.034
• 作为产物：
  描述：

  对氟硝基苯 在 钯 氢气 、 三甲基铝 、 potassium carbonate 作用下， 以 甲醇 、 二氯甲烷 、 二甲基亚砜 为溶剂， 生成 2-(3-Cyano-phenyl)-5-tetrazol-1-ylmethyl-2H-pyrazole-3-carboxylic acid (4-benzoimidazol-1-yl-phenyl)-amide
  参考文献：
  名称：

  SAR and factor IXa crystal structure of a dual inhibitor of factors IXa and Xa

  摘要：

  Modifications to the P4 moiety and pyrazole C3 substituent of factor Xa inhibitor SN-429 provided several new compounds, which are 5-10nM inhibitors of factor IXa. An X-ray crystal structure of one example complexed to factor IXa shows that these compounds adopt a similar binding mode to that previously observed with pyrazole inhibitors in the factor Xa active site both with regard to how the inhibitor binds and the position of Tyr99.

  DOI：

  10.1016/j.bmcl.2004.08.034